CRSP: crisprtx.com Company Aggregate Debts

Symbol and logo of brand CRISPR Therapeutics (CRSP)

Risks for CRISPR Therapeutics AG (CRSP) are linked to the high cost of therapy and the pace of its adoption. Experienced management has ensured financial autonomy through strategic alliances with market leaders. Debt capital dynamics demonstrate resilience, with the latest value recorded as 0.76. This trend is complemented by a commitment to ESG standards and strict ethical oversight when working with biomaterials.

CRSP CRISPR: Company Debts in the range 07/04/2022 - 11/01/2026

Metric breakdowns and analytics for CRISPR Therapeutics (CRSP)

- stock price and consensus target price:
Share Price CRISPR|CRSP - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization CRISPR Therapeutics Corp|CRSP - Enterprise Value
- balance sheet equity data:
Accounting Value per Share CRISPR Therapeutics|CRSP - Company Book Value|Market Value to Book Value crisprtx.com|CRSP - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient CRISPR Therapeutics AG|CRSP - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient CRISPR Therapeutics Inc|CRSP - Company Debts|Debts to Book Capitalization Ratio CRISPR Therapeutics Corp|CRSP - Company Long-Term Debt|Company Short-Term Loans and Borrowings CRISPR Therapeutics|Intermediate Coverage Ratio crisprtx.com
- business earnings and investment ratios data:
CRSP - Net Income
Fundamental company analysis:CRISPR - CRSP
Core merchandise of CRISPR Therapeutics Corp

This metric aggregates all external borrowings of the company, allowing for an assessment of financial stability and insolvency risk when calculating the debt load. By analyzing the enterprise's credit burden, an investor can determine whether CRISPR Therapeutics AG (CRSP) possesses sufficient liquidity to sustain its research and development amid geopolitical disruptions and sanction restrictions that block the cross-border logistics of biomaterials and international scientific cooperation.

Competitors of CRISPR Therapeutics AG

Tempus AI, Inc. - Company Aggregate Debt|Company Aggregate Debts QGEN (Qiagen N.V.)|Company Aggregate Debts ionispharma.com IONS|Repligen - Company Aggregate Debts|Avidity Biosciences Inc (RNA) - Company Total Debt|Sema4 (WGS) - Company Debts|Ultragenyx Corp - Aggregate Debt Obligations|BEAM (Beam Therapeutics Inc.) - Company Aggregate Debts|sarepta.com (SRPT) - Company Total Debt Obligations|Company Debts Twist Bioscience, Inc. (TWST)|Company Total Debt Obligations 10x Genomics Inc|Company Debts Intellia NTLA|STOK (Stoke Corp) - Company Aggregate Indebtedness|BLFS - Company Debts|Aggregate Debt Obligations WVE (wavelifesciences.com)|MAZE (Maze Therapeutics) - Company Total Debt|Sionna Therapeutics, Inc. - Aggregate Debt Obligations|Company Total Debt PRME|TSHA (Taysha Corp) - Company Cumulative Indebtedness|Company Aggregate Debts QURE|MGTX (meiragtx.com) - Aggregate Debt Obligations|Company Aggregate Debts RGNX (REGENXBIO)|Solid Biosciences Inc (SLDB) - Company Cumulative Debt|OCGN - Company Debts|Aggregate Debt Obligations PACB (PacBio Corp)|BNTC: Company Aggregate Debts|designtx.com (DSGN) - Company Aggregate Debts|Company Debts Rocket Pharmaceuticals, Inc.|4DMT - Company Aggregate Indebtedness|Company Aggregate Debts LXEO|KRRO - Company Cumulative Debt|Editas Medicine, Inc. - Company Total Debt|Company Aggregate Debts silence-therapeutics.com SLN|PRQR: Company Total Debt|Codexis, Inc. - Company Cumulative Indebtedness|SGMO: Company Aggregate Debts|NAUT - Company Total Debt Obligations|MGX (Metagenomi, Inc.) - Company Aggregate Debts|Company Total Debt precisionbiosciences.com (DTIL)|Company Debts Generation Bio Co. (GBIO)|Company Total Debt Obligations Boundless Bio Inc.|Exicure - Company Total Debt|Aggregate Debt Obligations IMNN|RXi Pharmaceuticals - Company Aggregate Debts|MBIO - Company Aggregate Debts|RNAZ: Company Aggregate Debts|Company Total Indebtedness Bionano Genomics BNGO|APDN (Applied DNA) - Company Aggregate Debts|Company Total Debt bluebird bio, Inc (BLUE)|Company Debts ImmunoPrecise Antibodies (IPA)|OMGA (omegatherapeutics.com) - Aggregate Debt Obligations|Company Debts Singular Genomics OMIC|Company Total Debt Obligations Regulus Therapeutics, Inc. (RGLS)|SYRS - Company Debts|Company Aggregate Indebtedness TBIO|TCON: Company Aggregate Debts|Company Aggregate Debt UBX